Equalizes negotiation period for small-molecule and biologic drugs under the Drug Price Negotiation Program.
The bill amends title XI of the Social Security Act to extend the negotiation period for biologic drugs to match that of small-molecule drugs under the Drug Price Negotiation Program. The change sets the negotiation period to 11 years, aligning it with small-molecule drugs. The amendment will take effect as if included in the enactment of Public Law 117–169.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.